{
  "data": {
    "indicator": {
      "slug": "long-term-annual-sales-outlook",
      "name": "Long-term annual sales outlook",
      "definition": "Projected long-term annual sales revenue target.",
      "unit": "GBP",
      "scale": "billion",
      "default_unit": "GBP",
      "default_scale": "billion"
    },
    "scale": "billion",
    "unit": "GBP",
    "region": {
      "code": "GLOBAL",
      "name": "Global",
      "type": "world"
    },
    "points": [
      {
        "period_start": "2031-01-01",
        "period_label": "2031",
        "value": 40,
        "scale": "billion",
        "unit": "GBP",
        "value_type": "forecast",
        "statistic_id": "stat_1V3Z865SSN2HW20Y3VVR25RJ76",
        "url": "https://statorigin.org/stat/stat_1V3Z865SSN2HW20Y3VVR25RJ76",
        "source_org": "GSK",
        "source": {
          "org": "GSK",
          "org_short_name": "GSK",
          "document_title": "GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026",
          "document_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/",
          "locator": "Growth outlooks:",
          "published_date": null
        }
      }
    ],
    "available_regions": [
      "GLOBAL"
    ]
  },
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 1
  }
}